(Il Sole 24 Ore Radiocor) - Milano, 7 apr - Gilead Sciences said it had agreed to buy German clinical-stage biotechnology company Tubulis for up to 5 billion dollars.

The acquisition significantly expands Gilead's antibody-drug conjugates capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize patient benefit, Gilead said.

Under the deal, Gilead will pay an initial 3.15 billion dollars in cash for Tubulis along with up to 1.85 billion in contingent milestone payments.

The California-based company said it planned to finance the transaction with a combination of cash on hand and senior unsecured notes.

The transaction is expected to close in the second quarter of.

2026.

(RADIOCOR) 07-04-26 15:20:55 (0424) 5 NNNN